FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386877852> ?p ?o ?g. }

• W4386877852 abstract "The impact of upadacitinib on rheumatoid arthritis (RA) symptoms was evaluated during the first 12 weeks of treatment via patient-reported outcomes (PROs) using a mobile health application (app).Participating rheumatologists from the CorEvitas RA Registry (prospective, observational cohort) recruited patients with RA initiating upadacitinib treatment. A modified version of the ArthritisPower® app was used to collect PROs, including the Routine Assessment of Patient Index Data 3 (RAPID3), duration of morning joint stiffness, and the Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue 7a Short Form at baseline and weeks 1-4, 8, and 12. RAPID3 responses over time were assessed using Kaplan-Meier estimation to determine the proportion of patients achieving disease activity improvement and minimal clinically important difference (MCID). Results were analyzed for all patients initiating upadacitinib and a subsample of TNF inhibitor (TNFi)-experienced patients with moderate to severe disease at baseline.A total of 103 patients with RA initiating upadacitinib (62.1% TNFi-experienced) were included. At week 12, 53 patients (51.4%) completed the study and provided PRO data via the app. Among all patients, improvements in RAPID3, pain, morning stiffness, and fatigue were observed at week 1 and were maintained or further improved through week 12. At week 12, 37.5% of patients achieved RAPID3 low disease activity. Starting at week 1, improvements in RAPID3 disease activity category (19.4% of patients) and achievement of MCID (16.3%) were reported, with nearly 50% of patients achieving these outcomes by week 4 (RAPID3 category: 48.8%; MCID: 49.2%) and 60% by week 12 (RAPID3 category: 59.6%; MCID: 59.8%). TNFi-experienced patients generally reported similar outcomes. Patient-reported medication convenience and compliance were generally high.In this real-world cohort of patients with RA, treatment with upadacitinib was associated with early and significant improvement in RAPID3, pain, morning stiffness, and fatigue regardless of prior TNFi experience. Clinically meaningful improvement in RAPID3 patient-reported disease activity was observed as early as week 1, with continued improvement reported through week 12." @default.
• W4386877852 created "2023-09-21" @default.
• W4386877852 creator A5001011559 @default.
• W4386877852 creator A5012346282 @default.
• W4386877852 creator A5012348347 @default.
• W4386877852 creator A5032296525 @default.
• W4386877852 creator A5040352377 @default.
• W4386877852 creator A5047907867 @default.
• W4386877852 creator A5060436528 @default.
• W4386877852 creator A5079841694 @default.
• W4386877852 creator A5079855923 @default.
• W4386877852 creator A5088741186 @default.
• W4386877852 creator A5090074119 @default.
• W4386877852 date "2023-09-20" @default.
• W4386877852 modified "2023-10-02" @default.
• W4386877852 title "A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis" @default.
• W4386877852 cites W2002438631 @default.
• W4386877852 cites W2017391495 @default.
• W4386877852 cites W2038593306 @default.
• W4386877852 cites W2059539909 @default.
• W4386877852 cites W2144317224 @default.
• W4386877852 cites W2289810507 @default.
• W4386877852 cites W2462711463 @default.
• W4386877852 cites W2565522107 @default.
• W4386877852 cites W2595012400 @default.
• W4386877852 cites W2622000437 @default.
• W4386877852 cites W2627037103 @default.
• W4386877852 cites W2770642598 @default.
• W4386877852 cites W2807791746 @default.
• W4386877852 cites W2808333862 @default.
• W4386877852 cites W2882327091 @default.
• W4386877852 cites W2896090530 @default.
• W4386877852 cites W2916926950 @default.
• W4386877852 cites W2946233321 @default.
• W4386877852 cites W2961111920 @default.
• W4386877852 cites W2964887480 @default.
• W4386877852 cites W2996668941 @default.
• W4386877852 cites W3014146563 @default.
• W4386877852 cites W3041856700 @default.
• W4386877852 cites W3080569092 @default.
• W4386877852 cites W3092992115 @default.
• W4386877852 cites W3113341258 @default.
• W4386877852 cites W3124719938 @default.
• W4386877852 cites W3127587557 @default.
• W4386877852 cites W3138746090 @default.
• W4386877852 cites W4220790715 @default.
• W4386877852 cites W4223518514 @default.
• W4386877852 cites W4229450458 @default.
• W4386877852 cites W4282924216 @default.
• W4386877852 cites W4306152450 @default.
• W4386877852 cites W4314447493 @default.
• W4386877852 doi "https://doi.org/10.1007/s40744-023-00594-6" @default.
• W4386877852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37728861" @default.
• W4386877852 hasPublicationYear "2023" @default.
• W4386877852 type Work @default.
• W4386877852 citedByCount "0" @default.
• W4386877852 crossrefType "journal-article" @default.
• W4386877852 hasAuthorship W4386877852A5001011559 @default.
• W4386877852 hasAuthorship W4386877852A5012346282 @default.
• W4386877852 hasAuthorship W4386877852A5012348347 @default.
• W4386877852 hasAuthorship W4386877852A5032296525 @default.
• W4386877852 hasAuthorship W4386877852A5040352377 @default.
• W4386877852 hasAuthorship W4386877852A5047907867 @default.
• W4386877852 hasAuthorship W4386877852A5060436528 @default.
• W4386877852 hasAuthorship W4386877852A5079841694 @default.
• W4386877852 hasAuthorship W4386877852A5079855923 @default.
• W4386877852 hasAuthorship W4386877852A5088741186 @default.
• W4386877852 hasAuthorship W4386877852A5090074119 @default.
• W4386877852 hasBestOaLocation W43868778521 @default.
• W4386877852 hasConcept C111278954 @default.
• W4386877852 hasConcept C126322002 @default.
• W4386877852 hasConcept C168563851 @default.
• W4386877852 hasConcept C1862650 @default.
• W4386877852 hasConcept C188816634 @default.
• W4386877852 hasConcept C2777575956 @default.
• W4386877852 hasConcept C71924100 @default.
• W4386877852 hasConcept C72563966 @default.
• W4386877852 hasConceptScore W4386877852C111278954 @default.
• W4386877852 hasConceptScore W4386877852C126322002 @default.
• W4386877852 hasConceptScore W4386877852C168563851 @default.
• W4386877852 hasConceptScore W4386877852C1862650 @default.
• W4386877852 hasConceptScore W4386877852C188816634 @default.
• W4386877852 hasConceptScore W4386877852C2777575956 @default.
• W4386877852 hasConceptScore W4386877852C71924100 @default.
• W4386877852 hasConceptScore W4386877852C72563966 @default.
• W4386877852 hasFunder F4320309117 @default.
• W4386877852 hasLocation W43868778521 @default.
• W4386877852 hasLocation W43868778522 @default.
• W4386877852 hasOpenAccess W4386877852 @default.
• W4386877852 hasPrimaryLocation W43868778521 @default.
• W4386877852 hasRelatedWork W2045151582 @default.
• W4386877852 hasRelatedWork W2082406232 @default.
• W4386877852 hasRelatedWork W2156283049 @default.
• W4386877852 hasRelatedWork W2316954211 @default.
• W4386877852 hasRelatedWork W2326094713 @default.
• W4386877852 hasRelatedWork W2427075784 @default.
• W4386877852 hasRelatedWork W2617939361 @default.
• W4386877852 hasRelatedWork W2761967325 @default.
• W4386877852 hasRelatedWork W4210646529 @default.
• W4386877852 hasRelatedWork W4238056209 @default.

• next